Understand PROTACs and Molecular Degraders: A Reading Framework for Early Clinical Data
Quick Answer
PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit an E3 ubiquitin ligase to a target protein, triggering its ubiquitination and degradation by the proteasome. Unlike traditional inhibitors that block a protein's active site, PROTACs eliminate the protein itself. As of 2026, the field is on the verge of its first approval: vepdegestrant (ARV-471), an ERα degrader, has submitted an NDA for ESR1-mutated ER+/HER2− advanced breast cancer. Over 30 PROTACs are in clinical trials, mostly in oncology [citation:3]. Reading early data requires attention to degradation depth (DC50), selectivity, and whether the trial was designed for safety or efficacy. This page explains the mechanism and how to read the evidence; it does not recommend any product.
What a PROTAC is, and how it differs from an inhibitor
A traditional small-molecule inhibitor works by occupying a binding pocket on a target protein, blocking its activity. This approach requires the protein to have a druggable pocket, and it often requires high sustained drug concentrations to maintain occupancy.
A PROTAC works differently. It is a heterobifunctional molecule with two ends: one binds the target protein, the other binds an E3 ubiquitin ligase (commonly CRBN or VHL). By bringing the two proteins into proximity, the PROTAC induces ubiquitination of the target, which is then recognized and destroyed by the proteasome [citation:2]. This is an event-driven mechanism rather than an occupancy-driven one: the PROTAC acts catalytically and can be recycled after each degradation event.
The practical implication is that PROTACs can, in principle, target proteins that lack a druggable active site — the so-called "undruggable" targets. They also degrade the entire protein, not just block one function, which may produce different downstream effects than inhibition.
Molecular glues: a related but distinct class
Molecular glues are smaller molecules that induce protein-protein interactions without the bifunctional architecture of a PROTAC. They often work by reshaping the surface of an E3 ligase or a target protein so that the two interact. The distinction matters for reading data: molecular glues and PROTACs are sometimes grouped under "targeted protein degradation," but their pharmacology, selectivity profiles, and resistance mechanisms can differ [citation:14].
The clinical landscape in 2026
The most advanced program is vepdegestrant (ARV-471), an oral PROTAC that degrades estrogen receptor alpha (ERα). It has completed a Phase III trial (VERITAC-2) in ESR1-mutant ER+/HER2− advanced breast cancer and an NDA has been submitted to the FDA [citation:3][citation:8]. The proposed indication is for patients previously treated with endocrine-based therapy.
Beyond vepdegestrant, more than 30 PROTACs are in clinical trials across oncology, with targets including AR (androgen receptor, e.g., ARV-110), BRD4, and others [citation:3]. Most are in Phase I or early Phase II. This means the evidence base for most PROTACs is still early-phase: small sample sizes, single-arm designs, and primary endpoints focused on safety and dose-finding rather than efficacy.
How to read early PROTAC data: four questions
| Question | What to look for | Why it matters |
|---|---|---|
| What is the degradation depth? | DC50 (concentration required for 50% degradation) and maximum degradation percentage | A PROTAC that binds but does not degrade effectively is functionally an inhibitor with extra steps |
| What is the selectivity? | Degradation of related proteins (e.g., other nuclear receptors) at relevant concentrations | PROTACs can degrade off-target proteins if the warhead is not selective |
| What was the trial designed to measure? | Primary endpoint: safety/dose-finding vs. efficacy | Phase I data cannot establish superiority over standard treatment |
| Is the data peer-reviewed or presented in a filing? | FDA review documents, peer-reviewed papers, or conference abstracts | Regulatory filings contain the most detailed nonclinical and clinical data |
What the vepdegestrant filing shows about the class
The FDA review documents for vepdegestrant provide a detailed view of how a PROTAC is characterized. The filing describes vepdegestrant as a potent, selective, orally bioavailable PROTAC that binds ER and CRBN, forms a ternary complex, and induces ER polyubiquitination and degradation [citation:1]. Preclinically, it degraded both wild-type and mutant ER and showed greater ER degradation than fulvestrant in a PDX model [citation:7].
The filing also illustrates class-level challenges. Vepdegestrant is a large molecule (beyond Rule of 5), has CYP3A4-mediated drug-drug interactions, and inhibits P-gp and BCRP transporters [citation:7][citation:15]. These are not unique to vepdegestrant; they reflect the physicochemical properties of PROTACs generally, and they matter for how the drug is used in practice.
Who This Page Is NOT For
- Readers seeking a recommendation of a specific PROTAC, trial, or center.
- Readers seeking a case evaluation or a referral to a trial site.
- Readers seeking a prediction of treatment response.
- Readers seeking confirmation that a PROTAC is "better" than an existing therapy — most are still in early-phase testing.
CancerCareE does not provide these services. This page is an educational reading framework.
Memory Anchor
Myth: "PROTACs are just a new way to inhibit a protein."
Reality: PROTACs degrade the protein by recruiting the cell's own ubiquitin-proteasome system. This is a mechanistically different approach from inhibition, with different implications for dosing, resistance, and selectivity. But degradation is not automatically better — it depends on which protein is degraded, how selectively, and in which context.
Frequently Asked Questions
What does "PROTAC" stand for?
Proteolysis-targeting chimera. It is a bifunctional molecule that binds a target protein and an E3 ubiquitin ligase, inducing degradation of the target by the proteasome [citation:2].
Is any PROTAC approved yet?
As of 2026, no PROTAC has been approved, but vepdegestrant (ARV-471) has submitted an NDA to the FDA for ESR1-mutated ER+/HER2− advanced breast cancer, and the review documents describe an overall positive benefit/risk profile based on progression-free survival improvements [citation:8]. The field is on the verge of a first approval, but approval status should be verified at the time of reading.
How is a PROTAC different from a molecular glue?
PROTACs are bifunctional: they have separate binding ends for the target and the E3 ligase. Molecular glues are typically smaller and induce protein-protein interactions by reshaping a protein surface, without the bifunctional architecture. Both fall under targeted protein degradation, but their pharmacology and selectivity profiles can differ [citation:14].
What is DC50?
DC50 is the concentration of a degrader required to achieve 50% degradation of the target protein. It is a common metric in preclinical PROTAC characterization. A low DC50 indicates potent degradation in the assay system, but it does not by itself predict clinical efficacy.
Why are PROTACs large molecules, and does that matter?
PROTACs are often larger than traditional small molecules because they contain two binding domains connected by a linker. Vepdegestrant, for example, is described as beyond Rule of 5 [citation:15]. This can affect oral bioavailability, drug-drug interactions, and tissue distribution — practical issues that appear in the FDA review documents.
Does this page recommend any PROTAC or trial?
No. This page explains the mechanism and how to read early data. It does not recommend, evaluate, or arrange access to any product, trial, or center, and it does not provide case evaluations or referrals.
References
- U.S. Food and Drug Administration. Vepdegestrant NDA 219835 Multidisciplinary Review. 2026. fda.gov
- Acharyya RK, et al. An Update on Clinically Advanced PROTAC Degraders and Their Synthesis. Molecules. 2025;31(1):33. doi:10.3390/molecules31010033. PubMed
- Wang X, et al. Overcoming breast cancer resistance through targeted protein degradation and next generation chimeras. Pharmacol Res. 2026;229:108239. doi:10.1016/j.phrs.2026.108239. PubMed
- U.S. Food and Drug Administration. Vepdegestrant NDA 219835 Chemistry Review. 2026. fda.gov
- Rana N, et al. Vepdegestrant (ARV-471): pharmacokinetics, drug metabolism and clinical translation of an oral ERα-targeting PROTAC. Expert Opin Drug Metab Toxicol. 2026. doi:10.1080/17425255.2026.2752978. PubMed
- Aliberti M, et al. Beyond Inhibition: Emerging Approaches in Ubiquitin-Proteasome-Mediated Protein Degradation for Precision Targeting. Chembiochem. 2026;27(21):e70589. doi:10.1002/cbic.70589. PubMed